Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00789750 · ClinicalTrials.gov registry record · Phase 3
Colesevelam as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus
A Phase 3 study, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 3
- Development phase
- 562
- Enrollment target
NCT00789750 is a Phase 3 study that has completed, run by Daiichi Sankyo. The registered enrollment target is 562 participants.
The verdict
NCT00789750, a Phase 3 study, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 562 participants
- Enrollment target
Study Summary
The current study investigates colesevelam as add-on therapy to pioglitazone to improve glycemic control in subjects with type 2 diabetes mellitus not adequately controlled with pioglitazone monotherapy or pioglitazone in combination with either metformin or a sulfonylurea. The study will evaluate if colesevelam add-on to pioglitazone therapy for type 2 diabetes mellitus will be safe, well tolerated, and efficacious.
Interventions
- DRUG Placebo
- DRUG Pioglitazone
- DRUG Colesevelam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 562 participants |
| Start Date | 2009-04 |
| Est. Completion | 2012-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00789750
The ClinicalTrials.gov registry entry for NCT00789750 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 562 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00789750 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00789750 about?
NCT00789750 is a clinical study titled "Colesevelam as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus". The current study investigates colesevelam as add-on therapy to pioglitazone to improve glycemic control in subjects with type 2 diabetes mellitus not adequately controlled with pioglitazone monotherapy or pioglitazone in combination with either metformin or a sulfonylurea. The study will evaluate i...
What is the current status of trial NCT00789750?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 562 participants. The study started on 2009-04. Estimated completion is 2012-07.
What interventions are being tested in trial NCT00789750?
The interventions under investigation include: Placebo (DRUG), Pioglitazone (DRUG), Colesevelam (DRUG).
Who is sponsoring clinical trial NCT00789750?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.